Related Experiment Video

Updated: Jul 11, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

445

Anti-obesity pharmacotherapy in adults with chronic kidney disease

Elizabeth Taber-Hight1, Ashley Gilmore1, Allon N Friedman1

  • 1Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Kidney International
|November 5, 2023
PubMed

Insights

New anti-obesity medications offer improved efficacy and safety for managing obesity, a key factor in chronic kidney disease (CKD) progression. This review examines these therapies from a kidney-centric perspective, highlighting future research needs.

Area of Science:

  • Nephrology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Obesity is a primary driver of kidney disease development and progression.
  • It significantly complicates the management of chronic kidney disease (CKD).
  • Past anti-obesity drugs had limited efficacy and safety concerns.

Purpose of the Study:

  • To review current and emerging pharmacologic anti-obesity therapies for adults.
  • To evaluate these treatments through a kidney-focused lens.
  • To identify key research questions for CKD patients.

Main Methods:

  • Literature review of pharmacologic anti-obesity treatments.
  • Analysis of drug efficacy, safety, and tolerability.
  • Focus on implications for patients with chronic kidney disease.

Main Results:

  • Recent advancements provide safer and more effective anti-obesity options.
  • These new therapies hold promise for transforming obesity management.
  • Understanding mechanisms and kidney-specific effects is crucial.

Conclusions:

  • Pharmacologic anti-obesity treatments are evolving rapidly.
  • A kidney-oriented approach is essential for optimizing therapy in CKD patients.
  • Further research is needed to address specific scientific questions in this population.
Keywords:
chronic kidney diseaseglucagon like peptide-1inflammationobesityoxidative stressweight loss

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

609
Robot-Assisted Kidney Transplantation07:30

Robot-Assisted Kidney Transplantation

Published on: July 19, 2021

3.6K

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
13
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage kidney disease (ESKD). At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate...
17
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
11
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
9